Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fludarabine - Bayer HealthCare Pharmaceuticals

X
Drug Profile

Fludarabine - Bayer HealthCare Pharmaceuticals

Alternative Names: 2-F-ara-AMP; 2-Fluoro-ARA-AMP; 2-Fluoroadenine-arabinoside; Beneflur; Fludara; Fludarabine phosphate; NSC 312887

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Southern Research Institute
  • Developer Bayer HealthCare Pharmaceuticals Inc.; Sanofi
  • Class Antineoplastics; Arabinonucleosides; Myeloablative agonists; Purine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 06 Aug 2014 Fludarabine licensed to Emcure Pharmaceuticals in India
  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer HealthCare Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top